RxDoctor Payments Data

Janneve Sankawulo, APRN

Family · Louisville, KYNPI 1356954366

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 28 payments — averaging $36.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$241
  • Boehringer Ingelheim$211
  • Bayer$186
  • GSK$125
  • Merck$64
  • Pfizer$60
  • plus $121 from 6 others

What the payments were for

  • Food & beverage$1,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,008 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$6,975
Medicare patients
48
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate22$19,484
EliquisApixaban14$17,654
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$14,397
MounjaroTirzepatide12$13,017
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,937
Albuterol Sulfate HfaAlbuterol Sulfate73$2,040
Lidocaine12$1,369
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$1,355
Ultra-Fine Short Pen NeedlePen Needle, Diabetic17$1,247
Atorvastatin Calcium141$1,032
Potassium Chloride51$897
Amlodipine Besylate178$866
Fluticasone Propionate42$710
Losartan Potassium87$686
Metoprolol Succinate51$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$64$19,48422 claims
PfizerEliquis$60$17,65414 claims
GSKTrelegy Ellipta$125$14,39711 claims
Lilly USA, LLCMounjaro$241$13,01712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →